Advisory

Choose your Partner

Both partners offer free account opening and dedicated support.

Angel One

Best for active traders

₹ 0 Account Opening Open Account →

Motilal Oswal

Best for long-term wealth

₹ 0 Account Opening Open Account →

IPO Open

Mon, Aug 24, 2026

IPO Close

Thu, Aug 27, 2026

Price Band

₹938 to ₹988

Market Cap*

₹6,244.43 Cr * on Upper Price IPO Details

IPO Details

  • IPO Date
    24 to 27 Aug, 2026
  • Listing Date
    Tue, Sep 1, 2026
  • Face Value
    ₹2 per share
  • Price Band
    ₹938 to ₹988
  • Lot Size
    15 Shares
  • Sale Type
    Fresh capital cum OFS
  • Issue Type
    Bookbuilding IPO
  • Listing At
    BSE, NSE
  • Employee Discount
    ₹90.00
  • Total Issue Size
    1,77,86,442 shares (agg. up to ₹1,757 Cr)
  • Fresh Issue
    15,21,261 shares (agg. up to ₹150 Cr)
  • Offer for Sale
    1,62,65,181 shares of ₹2 (agg. up to ₹1,607 Cr)
  • Share Holding Pre Issue
    6,16,81,496 shares
  • Share Holding Post Issue
    6,32,02,757 shares

IPO Timetable (Tentative)

  • IPO Open
    Mon, Aug 24, 2026
  • Allotment
    Fri, Aug 28, 2026
  • Credit of Shares
    Mon, Aug 31, 2026
  • IPO Close
    Thu, Aug 27, 2026
  • Refund
    Mon, Aug 31, 2026
  • Listing
    Tue, Sep 1, 2026

Issue Reservation

Investor Category Shares
QIB Not more than 50% of the Net Offer
Retail Not less than 35.00% of the Net Offer
NII Not less than 15% of the Net Offer

IPO Lot Size

Investors can bid for a minimum of 15 shares and in multiples thereof.

Application Lots Shares Amount
Retail (Min) 1 15 ₹14,820
Retail (Max) 13 195 ₹1,92,660
S-HNI (Min) 14 210 ₹2,07,480
S-HNI (Max) 67 1,005 ₹9,92,940
B-HNI (Min) 68 1,020 ₹10,07,760

Investor Category Reservations

Category Limit Cut-off
RII Up to ₹2 Lakhs Yes
sNII ₹2 Lakhs – ₹10 Lakhs No
bNII Above ₹10 Lakhs No
Employee (EMP) Up to ₹5 Lakhs Yes
Employee + RII/NII Up to ₹5Lakhs (EMP) + RII/NII limits Yes (EMP/RII)

About Symbiotec Pharmalab Ltd.

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions.

With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.

As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres.

Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.

Competitive Strengths:

  • Global leadership in corticosteroid and steroidal hormone APIs.
  • Long-standing relationships with domestic and international customers.
  • Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
  • Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
  • Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.

Company Financials (Restated)

Symbiotec Pharmalab Ltd.’s revenue increased by 15% and profit after tax (PAT) rose by 14% between the financial year ending with March 31, 2026 and March 31, 2025.  (Amount in ₹ Crore)

Period Ended 31 Mar 2026 31 Mar 2025 31 Mar 2024
Assets 1,780.79 1,579.65 1,294.79
Total Income 872.26 755.98 723.33
Profit After Tax 109.90 96.79 100.06
EBITDA 231.97 206.11 177.04
NET Worth 1,158.64 821.15 720.68
Reserves and Surplus 1,145.95 810.03 709.54
Total Borrowing 387.91 540.92 247.21

Recently Listed IPOs in Pharmaceuticals

Company Issue Type Issue Size Issue Price PE Ratio Listing Day Close Listing Gain/Loss % LTP
Hexagon Nutrition Ltd. Mainboard ₹138.87 Cr ₹45 22.69 ₹53.19 +18.20% ₹66.41
Sai Parenteral’s Ltd. Mainboard ₹408.79 Cr ₹392 72.19 ₹405.70 +3.49% ₹542.05
Corona Remedies Ltd. Mainboard ₹655.37 Cr ₹1062 43.47 ₹1,438.40 +35.44% ₹2,119.40

IPO Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

  • # Issue Objects
    Est Amt (₹ Cr.)
  • 1 Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
    112.50
  • 2 General corporate purposes
  • Total
    112.50

Key Performance Indicator (KPI)

Key Performance Indicator (KPI)

KPI Mar 31, 2026 Mar 31, 2025
ROE 11.19% 12.66%
ROCE 11.56% 11.80%
RoNW 9.48% 11.79%
PAT Margin 12.60% 12.80%
EBITDA Margin 26.59% 27.26%
NAV 184.69 150.17
Price to Book Value 5.35 6.58

 

IPO Valuation

Valuation Metric Pre IPO Post IPO
EPS (₹) 17.82 17.39
P/E (x) 55.44 56.81
Market Cap at Offer Price ₹6,094Cr. ₹6,244.43 Cr
  • The value will be calculated using Equity Dilution = Share Holding Pre Issue – Share Holding Post Issue
  • The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2026 available in RHP.
  • The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of March 31, 2026 available in RHP.

Shareholding Structure

Category Pre IPO Post IPO
Promoter and Promoter Group 34.47%
Public 65.53%
Total 100%

Company Promoters: Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.

Offer For Sale – Selling Shareholders

Name Category Estimated Amount (₹ cr.)
Satwani Holdings LLP Promoter 144.00
Rosewood Investments Other 988.00
India Business Excellence Fund III Corporate 475.00
Total 1,607.00

*Estimated Amount (₹ cr.) shown until the actual number of shares offered in OFS is entered.

IPO Registrar

MUFG Intime India Pvt.Ltd.

  • 022-49186000
  • symbiotecpharmalab.ipo@in.mpms.mufg.com
  • Visit Website

IPO Lead Manager(s)

  1. JM Financial Ltd.  (Past IPO Performance)
  2. Avendus Capital Pvt.Ltd.  (Past IPO Performance)
  3. Motilal Oswal Investment Advisors Ltd.  (Past IPO Performance)
  4. Nomura Financial Advisory & Securities (India) Pvt.Ltd.  (Past IPO Performance)

Lead Manager Reports

  • Lead Manager Performance Summary
  • Lead Manager Performance Tracker

Contact Details

Symbiotec Pharmalab Ltd. Address
385/2,
Pigdamber, Rau,
Mhow,
Indore, Madhya Pradesh, 453331

IPO FAQs

Symbiotec Pharmalab IPO is a main-board IPO of 1,77,86,442 equity shares of the face value of ₹2 aggregating up to ₹1,757 Crores. The issue is priced at ₹938 to ₹988. The minimum order quantity is 15.

The IPO opens on Mon, Aug 24, 2026, and closes on Thu, Aug 27, 2026.

MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Angel One customers can apply online in Symbiotec Pharmalab IPO using UPI as a payment gateway. Angel One customers can apply in Symbiotec Pharmalab IPO by login into Angel One Console (back office) and submitting an IPO application form.

Steps to apply in Symbiotec Pharmalab IPO through Angel One

Visit the Angel One website and login to Console.
Go to Portfolio and click the IPOs link.
Go to the ‘Symbiotec Pharmalab IPO’ row and click the ‘Bid’ button.
Enter your UPI ID, Quantity, and Price.
Submit IPO application form.
Visit the UPI App (net banking or BHIM) to approve the mandate.
Visit Angel One IPO Application Process Review for more detail.

The Symbiotec Pharmalab IPO opens on Mon, Aug 24, 2026 and closes on Thu, Aug 27, 2026.

Symbiotec Pharmalab IPO lot size is 15, and the minimum amount required for application is ₹14,820.

You can apply in Symbiotec Pharmalab IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don’t offer banking services. Read more detail about applying IPO online through Angel One , Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.

The finalization of Basis of Allotment for Symbiotec Pharmalab IPO will be done on Friday, August 28, 2026, and the allotted shares will be credited to your demat account by Mon, Aug 31, 2026. Check the Symbiotec Pharmalab IPO allotment status.

The Symbiotec Pharmalab IPO listing date is not yet announced. The tentative date of listing is Tue, Sep 1, 2026.

Stock Broker Reviews India

★ 2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

★ 2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

★ 2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

★ 2.34/5
Angel One Limited 2

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

★ 2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

★ 2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

Advertisments

Compare India's most trusted brokers side-by-side to find your perfect match.